Global X CleanTech vs Cytokinetics Inc — how do they compare? Global X CleanTech trades at $55.45 (market cap $25.33M), while Cytokinetics Inc trades at $62.02 (market cap $8.50B). The key difference: Cytokinetics Inc is far larger — about 335.6× Global X CleanTech's market cap, and Global X CleanTech is more actively traded (2,662 versus 2,395,556). Which is the better fit depends on your goals — on Pluang, investors hold Global X CleanTech for 42 Days and Cytokinetics Inc for 19 Days on average.
| CTEC | CYTK | |
|---|---|---|
Market Cap | $25.33M | $8.50B |
Volume | 2,662 | 2,395,556 |
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $87.26 |
52-Week Low | $50.82 | $54.76 |
Typical Hold Time | 42 Days | 19 Days |
Enterprise Value | — | $8.60B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →